Manoa Medical develops an advanced method of diagnosis and treatment of breast cancer.

The company's primary goals are to eliminate unnecessary breast surgeries, find the breast cancers that are often missed, facilitate the therapy delivery process, and save the company's healthcare system $2.3 billion annually. n

Michelson Diagnostics (MDL) is a UK-based independent company with products based on an optical imaging technology, called 'Multi-Beam OCT'. The company is primarily targeting cancer (screening, diagnosis, staging, treatment planning and guidance, and monitoring), but the products are also finding applications in commercial skin products research, in genetics (developmental biology) and in industrial metrology.

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.

Real Imaging is developing an imaging solution for breast cancer detection which is both accurate and patient-friendly. Real imaging's MIRA technology will increase correct detection rates and decrease the amount of false diagnoses for women of all ages around the globe.